Evercore Lifts PT on LinkedIn (LNKD) to $200, Likens to Salesforce.com (CRM)
Tweet Send to a Friend
Get Alerts LNKD Hot Sheet
Price: $182.35 +0.55%
Rating Summary:
18 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
18 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade LNKD Now!
Evercore Partners raised its price target on Overweight-rated LinkedIn (NYSE: LNKD) from $160 to $200 on anticipated multiple expansion.
"The anticipation stems from work performed with our Enterprise Software team, led by Kirk Materne, where we compare LinkedIn's business to several higher-multiple software peers (e.g., Salesforce.com nearer its IPO, Workday, and ServiceNow)," analyst Ken Sena said. "We conclude that on the basis of business mix, revenue growth, gross margins, and OCF, LinkedIn is worthy of comparable value, which would argue further multiple expansion."
Sena notes that one year following Salesforce.com (NYSE: CRM) IPO in 2004, it traded at 12x revenues versus the current 10x for LNKD. Five years following, CRM traded at 6.5x revs. "The similarities between LNKD and CRM include a predominantly enterprise-facing business model, consistent high double-digit revenue growth, multiple customer segments, large addressable markets, high gross margin and operating cash flow leverage, and a clear data advantage, suggesting strong moat characteristic," the analyst said.
A theoretical 5 Year $280 per share price could be argued, according to Sena. "This assumes for LNKD a similar level of sustained multiple contraction over the next five years as CRM (-11%)," he said. "Nevertheless, while this analysis is largely theoretical, we do see it as indicative of potential further share price upside for LinkedIn."
For an analyst ratings summary and ratings history on LinkedIn click here. For more ratings news on LinkedIn click here.
Shares of LinkedIn closed at $157.77 yesterday, with a 52 week range of $84.10-$165.20.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"The anticipation stems from work performed with our Enterprise Software team, led by Kirk Materne, where we compare LinkedIn's business to several higher-multiple software peers (e.g., Salesforce.com nearer its IPO, Workday, and ServiceNow)," analyst Ken Sena said. "We conclude that on the basis of business mix, revenue growth, gross margins, and OCF, LinkedIn is worthy of comparable value, which would argue further multiple expansion."
Sena notes that one year following Salesforce.com (NYSE: CRM) IPO in 2004, it traded at 12x revenues versus the current 10x for LNKD. Five years following, CRM traded at 6.5x revs. "The similarities between LNKD and CRM include a predominantly enterprise-facing business model, consistent high double-digit revenue growth, multiple customer segments, large addressable markets, high gross margin and operating cash flow leverage, and a clear data advantage, suggesting strong moat characteristic," the analyst said.
A theoretical 5 Year $280 per share price could be argued, according to Sena. "This assumes for LNKD a similar level of sustained multiple contraction over the next five years as CRM (-11%)," he said. "Nevertheless, while this analysis is largely theoretical, we do see it as indicative of potential further share price upside for LinkedIn."
For an analyst ratings summary and ratings history on LinkedIn click here. For more ratings news on LinkedIn click here.
Shares of LinkedIn closed at $157.77 yesterday, with a 52 week range of $84.10-$165.20.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Topeka Capital Raises Google (GOOG) Target to $999, Co. on 'Forefront of Innovation'
- Goldman Sees Blockbuster Potential for Bristol-Myers Squibb's (BMY) Nivolumab (PD-1)
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
